The Canadian government has given the green light to a startup for exporting psychedelic substances to Australia for medicinal purposes. Optimi Health Corp. is charged with the responsibility of shipping tablets laced with psilocybin, an active ingredient in magic mushrooms, and MDMA, as sanctioned by the health department.
The burgeoning demand goes beyond local magic mushrooms Ontario. Other countries are following Canada’s example and beginning to investigate and authorize the use of serotogenic compounds for medical applications.
You can confidently procure psychedelics online in Canada and unleash your innate potential through trustworthy sources.
[toc]Main Takeaways:
- Vancouver-based startup Optimi Health has earned a drug establishment license to export magic mushroom tablets to Australia.
- Australia allows licenced psychiatrists to use magic mushrooms in treating chronic depression.
- The treatment regimen comprises three sessions spread out over five to eight weeks, with each session lasting about eight hours.
Rise of Psilocybin Capsules in Canada
Optimi, a budding enterprise in Vancouver, intends to exploit its credentials to broaden the pharmaceutical market for psychedelic drugs and secure a first-mover advantage.
Seven firms have exported psilocybin, MDMA, or both, but strictly for clinical trial purposes. A Canada’s health department representative couldn’t confirm whether these exports were for regular patient use and refrained from revealing the companies due to security reasons.
This accomplishment positions Optimi among a handful of international suppliers, as the current market tends to favor clinical over recreational uses.
What Does the Pill Contain?
Although the company hasn’t disclosed the specific mushroom strain used in the pill, they do engage with a wide spectrum of strains including Albino Penis Envy, among others.
Optimi has established a 20,000-square-foot facility in Princeton, British Columbia, for cultivating, testing, and extracting its psychedelic mushrooms. This quaint town, home to around 3,000 residents, is situated three hours to the east of Vancouver.
Australia and Psychedelic Mushrooms: A Complex Relationship
About 20% of Australians between the ages of 16 and 85 are estimated to encounter a mental illness. PTSD (post-traumatic stress disorder) may affect approximately 11% of Australians at some point, and anxiety disorders are common amongst 17% of the populace.
Various methods are available for treating mental disorders, but not all are effective for every individual. Patients who fail to respond to certain treatments may struggle to find a beneficial alternative, thus increasing their vulnerability.
The Procedure Unveiled
Australia has spearheaded the medicinal use of psilocybin, allowing licensed psychiatrists to employ this regulated substance in treating resistant PTSD and depression.
In a groundbreaking decision in February, Australia’s Therapeutic Goods Administration (TGA) reclassified MDMA and shrooms for therapeutic purposes. The TGA asserted that these substances are safe when used in a medically supervised setting for patients grappling with severe mental disorders.
This step has been revolutionary for numerous mental health professionals and researchers. The usage of these substances will be strictly monitored; it’s not as simple as taking a pill and departing.
The standard treatment plan typically consists of three sessions spread over five to eight weeks. Each session extends to about eight hours, with the therapist staying with the patient the entire time.
Canada’s Role in Psilocybin Research
Canada has risen as a significant center for psilocybin research, considerably expanding our understanding of this compound. Health Canada, in collaboration with various institutions, is leading the investigation into the therapeutic potential of psilocybin for a range of mental health conditions.
Research institutions are no longer required to classify these substances as illegal or rely on unauthorized dispensaries or mushroom shops. The government now permits certain institutions to cultivate shrooms for research.
The increased accessibility to substances once deemed harmful allows researchers to deepen their understanding of their potential benefits to many individuals.
A Recurring Trend
During the 1950s, it was identified for the first time that this field held significant potential in addressing issues related to mental health and substance abuse, including alcoholism. Pioneers of this initial research included English psychiatrist Humphry Osmond and Canadian biochemist Abram Hoffer, who conducted their studies at the Saskatchewan Mental Hospital in Weyburn. The hospital experienced significant advancements under the leadership of then-premier Tommy Douglas, who provided the medical community with substantial freedom to investigate their medical theories.
Dr. Osmond and Dr. Hoffer initiated studies with LSD, mescaline, and peyote as potential alternatives to the harsh methods of electroshock and lobotomy. Their research took unexpected turns, promoting the idea that doctors, nurses, and other medical staff should experiment with these substances.
Canadian Health Research Institutes
Through the Institute of Neurosciences, Mental Health and Addiction, the Canadian Health Research Institutes sponsors three clinical trials aimed at studying the therapeutic efficacy and safety of psilocybin-assisted psychotherapy:
| Project Type | Study Focus | Research Institution | Lead Investigator | Budget for the Project |
| A controlled trial with random selection | Emotional distress at end-of-life in patients with advanced cancer stages | University of Toronto | Sarah Hales | $928,643 |
| Mechanisms supporting psychotherapy with psilocybin for alcohol use disorder treatment | Alcohol use disorder | University of Calgary | Leah Mayo | $1,000,000 |
| A randomized phase II clinical trial contrasting single dose vs dual psychedelic doses | Treatment-resistant depression | University of Toronto | Joshua Rosenblat | $1,000,000 |
This research funding will facilitate a more in-depth understanding of controlled substances’ benefits. The Government of Canada’s Canadian Drugs and Substances Strategy (CDSS) has made this possible.
Further Psychedelic Research
In Vancouver, psychiatrists have started a phase III clinical trial of MDMA, commonly known as ecstasy, for treating post-traumatic stress disorder (PTSD). The treatment involves three eight-hour MDMA sessions, with a month’s gap in between, and nine 90-minute sessions without the drug. Researchers consider this trial to be of historical importance as it is the first clinical testing of an illicit
It’s been over forty years since a psychedelic substance has been introduced.
Getting to Know Psilocybin
Psilocybin, a naturally occurring psychedelic compound, is found in certain types of mushrooms. Upon ingestion, it transforms into psilocin. The psilocin then stimulates the serotonin 5-HT2a receptors found on the cortical pyramidal cells in the brain, which act as the main processing hubs.
The compound is currently under investigation by local authorities for its potential benefits in treating depression, anxiety, substance addiction, and end-of-life distress, by encouraging introspection and spiritual enlightenment.
How Does It Help with Depression, PTSD, and Other Conditions?
The active component in the substance acts on several areas of the brain, making it potentially effective for diverse mental conditions. This therapy has already been used on numerous patients in Canada and Australia, with promising results and minimal side effects such as temporary anxiety or slightly increased blood pressure.
Impact on Neurobiology
- Activation of Serotonin Receptors: The compound functions as a partial agonist at serotonin receptors, especially the 5-HT2A subtype, which plays a key role in emotional processing and mood regulation.
- Regulation of Default Mode Network (DMN): It reduces DMN activity, promoting introspection, curbing rigid thought patterns, and fostering emotional flexibility.
- Stimulation of Prefrontal and Limbic Regions: The antidepressant effects of the compound result from its influence on the prefrontal and limbic regions of the brain, including the amygdala. In depressed individuals, the response to emotional stimuli is typically reduced. The compound enhances the response to positive emotional stimuli in the right amygdala and normalizes the response to negative or neutral emotional stimuli.
Effects on Psychology and Emotions:
- Generation of Positive Mood States: It promotes feelings of euphoria, interconnectedness, and emotional openness during and following the experience.
- Enhanced Emotional Processing: The psychedelic experience may allow individuals to confront and process deep-seated emotions, traumatic memories, or existential concerns in a supportive setting.
- Spiritual and Existential Insights: Research from Johns Hopkins University and Imperial College London suggests that it could result in long-term positive changes, such as improved wellness, increased life satisfaction, and spiritual growth.
What Can You Discover at Your Local Magic Mushroom Shops?
Interested in how this substance might impact your mental health? Explore your local magic mushroom stores to find a product that caters to your requirements.
| Product | Quantity | Potency | Benefits |
| Evoke – Medicinal Mushrooms | 20 | 100mg or 200mg | Improves mood, triggers creative thinking, and enhances focus and productivity |
| Ground Sounds – Microdose Capsules – Super Freak | 30 | 50mg, 100mg, and 250mg | Supports better health and boosts overall quality of life |
| Kind Stranger – Microdose Capsules – Sidekick | 30 | 100mg | Encourages clarity, creativity, and concentration. Includes a robust mix of clinical strength adaptogenic herbs |
| Osmosis – Brain Boost | 30 | 100mg or 200mg | Provides cognitive and energy benefits |
International Acceptance of Psilocybin
Canada isn’t the only country recognizing the benefits of magic mushrooms for mental health problems. Countries like Australia also endorse the use of these hallucinogens for conditions such as depression and PTSD. They procure high-quality psychedelic capsules from trusted sources. With proper guidance, patients can significantly improve their life quality. Micro Zoomiez Canada, a magic mushroom retailer, offers a variety of products, from tablets to LSD edibles.
Frequently Asked Questions
How do psilocybin and MDMA relate?
Both psilocybin and MDMA have therapeutic potential by enhancing mental health. Psilocybin interacts with serotonin 2A receptors and is effective in treating depression and addiction.
Conversely, MDMA promotes empathy and is beneficial in PTSD treatments. It demonstrates potential in improving emotional processing and
Despite being classified as a controlled substance, it still has therapeutic outcomes.
Is this treatment option accessible to all Australians?
In Australia, not everyone can access this treatment option. Individuals must first undergo an evaluation to ascertain if they are suitable candidates for using the substance. Factors such as existing heart conditions and a history of psychosis are considered during this evaluation. This treatment is reserved for patients who have not found relief from traditional treatments for conditions such as depression, anxiety, or PTSD.
What implications does Canada’s mushroom export have?
With its intention to lead the psychedelics market, much like its stance on cannabis, Canada is establishing a path for more companies to produce high-quality products. As a result, Canada could become a leader in the hallucinogen market, strengthening its economy and providing other countries with access to these treatments. This move could also prevent other countries from obtaining their hallucinogens from illegal dispensaries or suppliers, thus ensuring safety.
Interesting Articles You Might Like:
